A National Service Evaluation of Paclitaxel Pre-medication Regimes for the Prevention of Hypersensitivity during a period of Ranitidine Shortage - initial data analysis
Emma Foreman 
Pinkie Chambers
Calum Polwart
Oncology, Pharmacy, Data, Real-World Outcomes, Software, Open Source
This poster was presented by Emma Foreman at the British Oncology Pharmacy Association Annual Symposium. The poster summarised some work evaluating the impact of omitting ranitidine from paclitaxel infusions. Ranitidine was withdrawn from the market due to concerns about contamination. However, ranitidine had been widely considered an essential component of the premedication for paclitaxel to reduce the risk of allergic reactions.
Foreman, Chambers and myself collated data from a number of centres to evaluate the impact of using an alternative H2 antagonist or no antagonist. This work has subsequently been published in the British Journal of Clinical Pharmacology as described on this page of this site.
The abstracts for this meeting are published in theJournal of Oncology Pharmacy Practice. The poster is available on Research Gate.
— Content on this website has been produced with reasonable care. However, errors can occur. Opinions change over time. Code that worked at the time of publication may no longer work. Users of all content from this site do so at their own risk.
Reuse
Copyright
Citation
@article{foreman2021,
author = {Foreman, Emma and Chambers, Pinkie and Polwart, Calum},
publisher = {Sage Journals},
title = {A {National} {Service} {Evaluation} of {Paclitaxel}
{Pre-medication} {Regimes} for the {Prevention} of
{Hypersensitivity} During a Period of {Ranitidine} {Shortage} -
Initial Data Analysis},
journal = {Journal of Oncology Pharmacy Practice},
volume = {28},
number = {2\_suppl},
date = {2021-10-09},
url = {https://doi.org/10.1177/10781552221078082},
doi = {10.1177/10781552221078082},
issn = {1078-1552},
langid = {en}
}